Ruxolitinib is the recommended medical treatment of Primary andpost-Polycythemia Vera/post-Essential Thrombocythemia Myelofibrosis(PMF,PPV/PET-MF)withintermediate/highriskcarryingsymptomaticsplenomegaly and/or MF-related symptoms [1]. In prospective clinicaltrials,60–80%ofpatientsachievedareductioninspleenlength≥25%duringtreatment[2,3].Thecorrelationbetweenspleenreductionswithoutcomeisstillcontroversial.InaPhase1/2trial,patientswith≥50%reduction in spleen-length response (palpation) were found to have asignificantlybettersurvival,anda5dlincreasefrombaselineinspleenvolume correlated with worse outcome in a pooled analysis of theCOMFORT trials [4,5]. Conversely, a spleen response (SR) defined ac-cording to the International Working Group on Myelofibrosis Researchand Treatment criteria [6] atweek 24 wasnot found tocorrelate withbettersurvivalinalargecohortofruxolitinib-treatedpatientsafterad-justment for the International Prognostic Score System (IPSS) and thedynamic-IPSS(DIPSS)risk
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients
Cavazzini, Francesco;Cuneo, Antonio;
2018
Abstract
Ruxolitinib is the recommended medical treatment of Primary andpost-Polycythemia Vera/post-Essential Thrombocythemia Myelofibrosis(PMF,PPV/PET-MF)withintermediate/highriskcarryingsymptomaticsplenomegaly and/or MF-related symptoms [1]. In prospective clinicaltrials,60–80%ofpatientsachievedareductioninspleenlength≥25%duringtreatment[2,3].Thecorrelationbetweenspleenreductionswithoutcomeisstillcontroversial.InaPhase1/2trial,patientswith≥50%reduction in spleen-length response (palpation) were found to have asignificantlybettersurvival,anda5dlincreasefrombaselineinspleenvolume correlated with worse outcome in a pooled analysis of theCOMFORT trials [4,5]. Conversely, a spleen response (SR) defined ac-cording to the International Working Group on Myelofibrosis Researchand Treatment criteria [6] atweek 24 wasnot found tocorrelate withbettersurvivalinalargecohortofruxolitinib-treatedpatientsafterad-justment for the International Prognostic Score System (IPSS) and thedynamic-IPSS(DIPSS)risk| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0145212618302406-main.pdf
solo gestori archivio
Descrizione: Full text editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
1.04 MB
Formato
Adobe PDF
|
1.04 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
